Difference between revisions of "Myelodysplastic syndrome"
Jump to navigation
Jump to search
m (Text replace - ", et al. " to " et al. ") |
|||
| Line 68: | Line 68: | ||
==Clofarabine (Clolar)== | ==Clofarabine (Clolar)== | ||
| − | ===Regimen #1, Faderl | + | ===Regimen #1, Faderl et al. 2010=== |
''Initial dose was too toxic; 20 mg/m2 was final dose level'' | ''Initial dose was too toxic; 20 mg/m2 was final dose level'' | ||
*[[Clofarabine (Clolar)]] 20 mg/m2 PO daily on days 1-5 | *[[Clofarabine (Clolar)]] 20 mg/m2 PO daily on days 1-5 | ||
| Line 77: | Line 77: | ||
*"Supportive care included anti-infectious prophylaxis (eg, levaquin, valacyclovir, and itraconazole or voriconazole), hematopoietic growth factors, and transfusions as judged indicated by the treating physician." In order to decrease risk of liver function abnormalities, no antifungals were given on the days where clofarabine was given. | *"Supportive care included anti-infectious prophylaxis (eg, levaquin, valacyclovir, and itraconazole or voriconazole), hematopoietic growth factors, and transfusions as judged indicated by the treating physician." In order to decrease risk of liver function abnormalities, no antifungals were given on the days where clofarabine was given. | ||
| − | ===Regimen #2, Faderl | + | ===Regimen #2, Faderl et al. 2012=== |
''Lower dose was less toxic; clinical activity was comparable'' | ''Lower dose was less toxic; clinical activity was comparable'' | ||
*[[Clofarabine (Clolar)]] 15 mg/m2 or 30 mg/m2 IV over 1 hour daily on days 1-5 | *[[Clofarabine (Clolar)]] 15 mg/m2 or 30 mg/m2 IV over 1 hour daily on days 1-5 | ||
| Line 104: | Line 104: | ||
'''28-day cycles''' | '''28-day cycles''' | ||
| − | ===Regimen #1, Kantarjian | + | ===Regimen #1, Kantarjian et al. 2007=== |
*[[Decitabine (Dacogen)]] 20 mg/m2/day divided into 2 SC doses per day on days 1 to 5 | *[[Decitabine (Dacogen)]] 20 mg/m2/day divided into 2 SC doses per day on days 1 to 5 | ||
'''28-day cycles''' | '''28-day cycles''' | ||
| − | ===Regimen #2, Kantarjian | + | ===Regimen #2, Kantarjian et al. 2007=== |
*[[Decitabine (Dacogen)]] 10 mg/m2 IV over 1 hour once per day on days 1 to 10 | *[[Decitabine (Dacogen)]] 10 mg/m2 IV over 1 hour once per day on days 1 to 10 | ||
'''28-day cycles''' | '''28-day cycles''' | ||
| − | ===Regimen #3, Kantarjian | + | ===Regimen #3, Kantarjian et al. 2006; Rüter et al. 2006=== |
*[[Decitabine (Dacogen)]] 15 mg/m2 IV over 3 hours every 8 hours on days 1 to 3 | *[[Decitabine (Dacogen)]] 15 mg/m2 IV over 3 hours every 8 hours on days 1 to 3 | ||
Revision as of 23:31, 17 October 2013
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Untreated
Alemtuzumab
Indication: Intermediate-1 MDS (RAEB-I, RA, or RARS)
Regimen
- Alemtuzumab (Campath) 1 mg IV once on day 1; then 10 mg IV once daily on days 2-11
11-day course of therapy
Supportive Medications:
- Pentamidine (Nebupent) dose not specified INH monthly for at least 6 months for PCP prophylaxis
- Valacyclovir (Valtrex) dose/schedule not specified until CD4 count >200/uL
- Ciprofloxacin (Cipro) dose/schedule not specified if ANC <500/uL
- Erythropoietin and G-CSF were permitted for severe anemia or neutropenia
References
- Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K, Wu CO, More K, Barrett AJ, Scheinberg P, Young NS. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol. 2010 Dec 10;28(35):5166-73. doi:10.1200/JCO.2010.29.7010. Epub 2010 Nov 1. link to original article contains verified protocol PubMed
Antithymocyte globulin (ATG)
Regimen
- Antithymocyte globulin (ATG) 40 mg/kg IV over 4-8 hours on days 1-4
- Prednisone (Sterapred) 1 mg/kg (minimum of 40 mg) PO on days 1-10, and then tapered to off during days 11-17
References
- Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997 Dec;99(3):699-705. PubMed
- Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, Liu J, Nakamura R, Young NS, Barrett AJ. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med. 2002 Aug 6;137(3):156-63. link to original article contains protocol PubMed
- Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 2003 Mar 15;101(6):2156-8. Epub 2002 Oct 31. link to original article contains protocol PubMed
- Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008 May 20;26(15):2505-11. Epub 2008 Apr 14. link to original article PubMed
Azacitidine (Vidaza)
Regimen #1, various
- Azacitidine (Vidaza) 75 mg/m2 SC or IV continuous infusion daily on days 1 to 7
28-day cycles, given for at least 4 cycles, then depending on study, continued for 3 cycles beyond complete remission, or if there was progressive disease or unacceptable toxicity
Regimen #2, Fili et al. 2013
Intended to be used for low-risk MDS patients who are symptomatic or intolerant to erythropoietin
- Azacitidine (Vidaza) 75 mg/m2 SC daily on days 1 to 5
28-day cycles x 8 cycles
Supportive medications:
- G-CSF or GM-CSF was allowed if ANC < 200 and/or systemic infection
- Erythropoiesis-stimulating agents were not allowed
- Antimicrobial and antifungal prophylaxis (agents not specified) given if ANC < 500
Regimen #3, Grövdal et al. 2010
Intended to be used for high-risk MDS patients in remission after induction therapy
- Azacitidine (Vidaza) 60 mg/m2 SC daily on days 1 to 5
28-day cycles
References
- Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15;20(10):2429-40. link to original article contains protocol PubMed
- Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20;24(24):3895-903. link to original article contains protocol PubMed
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223-32. Epub 2009 Feb 21. link to original article contains protocol PubMed
- Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010 Aug;150(3):293-302. doi: 10.1111/j.1365-2141.2010.08235.x. Epub 2010 May 20. link to original article contains verified protocol PubMed
- Filì C, Malagola M, Follo MY, Finelli C, Iacobucci I, Martinelli G, Cattina F, Clissa C, Candoni A, Fanin R, Gobbi M, Bocchia M, Defina M, Spedini P, Skert C, Manzoli L, Cocco L, Russo D. Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2013 May 22. [Epub ahead of print] link to original article contains verified protocol PubMed
Clofarabine (Clolar)
Regimen #1, Faderl et al. 2010
Initial dose was too toxic; 20 mg/m2 was final dose level
- Clofarabine (Clolar) 20 mg/m2 PO daily on days 1-5
4 to 8 week cycles x up to 12 cycles
Supportive medications:
- "Supportive care included anti-infectious prophylaxis (eg, levaquin, valacyclovir, and itraconazole or voriconazole), hematopoietic growth factors, and transfusions as judged indicated by the treating physician." In order to decrease risk of liver function abnormalities, no antifungals were given on the days where clofarabine was given.
Regimen #2, Faderl et al. 2012
Lower dose was less toxic; clinical activity was comparable
- Clofarabine (Clolar) 15 mg/m2 or 30 mg/m2 IV over 1 hour daily on days 1-5
4 to 8 week cycles x up to 12 cycles
Supportive medications:
- "Supportive care measures such as antibiotic prophylaxis (eg, levofloxacin, valacyclovir, and itraconazole or voriconazole), hematopoietic growth factors, and transfusions were provided as necessitated for optimal medical care of the patients." In order to decrease risk of liver function abnormalities, no antifungals were given on the days where clofarabine was given.
References
- Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 1;28(16):2755-60. doi: 10.1200/JCO.2009.26.3509. Epub 2010 Apr 26. link to original article contains verified protocol PubMed
- Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 1;118(3):722-8. doi:10.1002/cncr.26327. Epub 2011 Jul 12. link to original article contains verified protocol PubMed
Cyclosporine modified (Neoral)
Regimen
- Cyclosporine modified (Neoral) 5-6 mg/kg/day, divided into two equal doses PO BID, adjusted to maintain therapeutic cyclosporine level of 100-300 ng/mL
References
- Jonásova A, Neuwirtová R, Cermák J, Vozobulová V, Mociková K, Sisková M, Hochová I. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998 Feb;100(2):304-9. link to original article contains protocol PubMed
- Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008 May 20;26(15):2505-11. Epub 2008 Apr 14. link to original article PubMed
Decitabine (Dacogen)
Regimen
- Decitabine (Dacogen) 20 mg/m2 IV over 1 hour once per day on days 1 to 5
28-day cycles
Regimen #1, Kantarjian et al. 2007
- Decitabine (Dacogen) 20 mg/m2/day divided into 2 SC doses per day on days 1 to 5
28-day cycles
Regimen #2, Kantarjian et al. 2007
- Decitabine (Dacogen) 10 mg/m2 IV over 1 hour once per day on days 1 to 10
28-day cycles
Regimen #3, Kantarjian et al. 2006; Rüter et al. 2006
- Decitabine (Dacogen) 15 mg/m2 IV over 3 hours every 8 hours on days 1 to 3
6-week cycles x up to 6 to 8 cycles
Regimen #4, Garcia-Manero et al. 2013
Level of Evidence: Phase II
- Decitabine (Dacogen) 20 mg/m2 SC daily on days 1 to 3
28-day cycles +/- 3 days x up to 12 months
Regimen #5, Garcia-Manero et al. 2013
Level of Evidence: Phase II
- Decitabine (Dacogen) 20 mg/m2 SC weekly on days 1, 8, 15
28-day cycles +/- 3 days x up to 12 months
References
- Rüter B, Wijermans PW, Lübbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer. 2006 Apr 15;106(8):1744-50. link to original article contains protocol PubMed
- Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006 Apr 15;106(8):1794-803. link to original article contains protocol PubMed
- Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 1;109(1):52-7. Epub 2006 Aug 1. link to original article contains protocol PubMed
- Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. J Clin Oncol. 2013 Jun 3. [Epub ahead of print] link to original article contains verified protocol PubMed
Lenalidomide (Revlimid)
Regimen
- Lenalidomide (Revlimid) 10 mg PO daily
References
- List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. link to original article PubMed
- Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15;108(4):1158-64. Epub 2006 Apr 11. link to original article contains protocol PubMed
- List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65. link to original article contains protocol PubMed
- Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24. link to original article contains protocol PubMed
Lenalidomide and azacitidine
Levels of Evidence: Phase II
Regimen
- Lenalidomide (Revlimid) 10mg PO daily on days 1-21
- Azacitidine (Vidaza) 75 mg/m2/day on days 1-5
28-day cycles up to 7 cycles, with option to continue single agent azacitidine per MD discretion
References
- Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012 Dec 13;120(25):4945-51. doi: 10.1182/blood-2012-06-434639. Epub 2012 Aug 22. link to original article contains protocol PubMed
Lenalidomide and epoetin alfa
Levels of Evidence: Phase II
Regimen
- Lenalidomide (Revlimid) 10-15 mg PO daily
For 16 weeks; erythroid nonresponders or those with relapsed anemia then offered combined treatment:
- Lenalidomide (Revlimid) 10-15 mg PO daily
- Epoetin alfa (Procrit) 40,000 units SC weekly
Continue until treatment failure or limiting toxicity
References
- Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012 Oct 25;120(17):3419-24. doi:10.1182/blood-2012-03-415661. Epub 2012 Aug 30. link to original article contains protocol PubMed